Home
About
Overview
Sharing Data
ORCID
Help
History (38)
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
Cycle length statistics during human atrial fibrillation reveal refractory properties of the underlying substrate: a combined in silico and clinical test of concept study.
Miller-Dieker syndrome: lissencephaly and monosomy 17p.
Fluorescence in situ hybridization analysis with LIS1 specific probes reveals a high deletion mutation rate in isolated lissencephaly sequence.
Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas.
See All 38 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas.
Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. Science. 2014 Jan 17; 343(6168):309-13.
View in:
PubMed
subject areas
Animals
Carcinoma, Squamous Cell
Genetic Testing
Head and Neck Neoplasms
Humans
Lung Neoplasms
Mice
Mice, Knockout
Molecular Motor Proteins
Mutation
Myosin Heavy Chains
Nonmuscle Myosin Type IIA
RNA Interference
Transcription, Genetic
Tumor Suppressor Protein p53
Tumor Suppressor Proteins
authors with profiles
Jeremy Segal